Navigating Complexities in Advanced Glaucoma Management: A Case Report Integrating Insights from the LiGHT Trial

Introduction: Glaucoma, a leading cause of irreversible blindness, presents significant management challenges, especially in patients intolerant to standard treatments. Recent findings from the Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial offer new insights into alternative treatment strategies. Case Presentation: This report discusses the case of a 79-year-old woman with a longstanding history of open-angle glaucoma (AOG), who was intolerant to conventional glaucoma medications. Her treatment included multiple surgeries: trabeculectomies in her left eye and various laser therapies in her right eye. The LiGHT Trial findings, demonstrating the efficacy of Selective Laser Trabeculoplasty (SLT) in providing long-term disease control with a favorable safety profile, offer relevant insights into similar cases. Outcomes: As of the last examination, the patient's vision was 20/80 OD and 20/500 OS, with stable intraocular pressures and visual field loss. The case resonates with the LiGHT Trial's advocacy for SLT as a primary treatment option for managing glaucoma effectively. Conclusion: This case underscores the complexities of managing advanced glaucoma in patients intolerant to traditional medications and highlights the importance of personalized, evolving treatment strategies. The insights from the LiGHT Trial reinforce the potential of SLT as a viable primary treatment, aligning with the need for innovative approaches in glaucoma management.